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Abstract
Background: Antifibrotic agents are commonly utilized to enhance the success rates of trabeculectomy. Novel
approaches to further improve success rates and reduce the risks of complications are needed. The purpose
of this study was to compare intraocular pressure (IOP)-lowering efficacy and safety of trabeculectomy or combined
phacoemulsification and trabeculectomy with mitomycin-C (MMC) vs. Collagen Matrix (CM).
Methods: A prospective, multicenter, randomized controlled trial was performed. Ninety-five eyes of 94 patients with
uncontrolled glaucoma despite medical therapy, without previous incisional glaucoma surgery underwent
trabeculectomy (85 eyes) or combined phacoemulsification and trabeculectomy (10 eyes) and were randomized to
MMC or CM. One eye of each subject was analyzed. Patients were followed for 24 months. The criteria for complete
success were IOP >5 and ≤21 mmHg with at least a 20% reduction below medicated baseline without additional
glaucoma surgery or medications. The main outcome measures were complete success rates at 24 months with
Kaplan-Meier analysis and incidence of adverse events.
Results: The baseline IOPs were 20.4 ± 6.0 mmHg and 21.2 ± 6.1 (mean ± standard deviation, p = 0.49) on 3.2 ± 1.1
and 3.1 ± 1.0 medications (p = 0.53) compared to 11.8 ± 5.2 and 12.8 ± 3.7 (p = 0.36) on 0.5 ± 0.8 and 0.6 ± 1.0
medications (p = 0.63) at 2 years in the MMC and CM groups, respectively. Kaplan-Meier analysis demonstrated
complete success rates were similar in both groups at 24 months: 38.4 ± 7.6% with MMC and 56.2 ± 7.9% with
CM (mean ± standard error, p = 0.112, log rank test); however, a significantly higher incidence of failure due to
persistent hypotony was observed with MMC (p = 0.002).
Conclusions: Use of the CM implant at the time of trabeculectomy or combined phacoemulsification and
trabeculectomy is associated with similar complete success rates compared to adjunctive MMC; however,
the risk of persistent hypotony is higher with MMC.
Trial registration: ClinicalTrials.gov registration number NCT01440751.
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Background
Trabeculectomy remains the most frequently utilized
operation for eyes with severe glaucoma in which a low
target intraocular pressure (IOP) is desired [1]. Antifibrotic
therapy with mitomycin-C (MMC) or 5-fluorouracil
(5-FU) is a valuable adjunct to trabeculectomy for redu-
cing scarring and improving IOP-lowering efficacy.
Although extremely variable, due in part to different
definitions of success, demographic characteristics of
subjects and duration of follow-up, some recently
reported success and complication rates are less than
desirable [2–6].
Hsu et al. [7] demonstrated in a rabbit model of con-
junctival wound healing that full-thickness conjunctival
defects healed with less wound contraction and the for-
mation of more normal-appearing conjunctival stroma
when the wounds were grafted with a porous collagen
matrix composed of a collagen-glycosaminoglycan
copolymer compared to control eyes in which the con-
junctival defects were left bare. Chen et al. [8] further
advanced the concept of using a porous collagen matrix
(CM) implant as an adjunct to trabeculectomy. Their
approach was to use the implant to resist over-filtration
in the early post-operative period by acting as a physical
barrier and to maintain long-term pressure control by
promoting the development of a loosely organized scar
as the implant degrades. In a rabbit model, eyes under-
going trabeculectomy with CM implantation maintained
IOP reduction to 55% below baseline at day 28, whereas
control eyes undergoing trabeculectomy without CM
reverted to baseline IOP levels by day 21 [8].
The Ologen CM (Aeon Astron Europe B.V., Leiden,
The Netherlands) is a porous, disc-shaped implant that
is commercially available in two sizes, a 6-mm diameter
disc with a thickness of 2 mm and a 12-mm diameter
disc with a thickness of 1 mm. It is composed of a colla-
gen-glycosaminoglycan copolymer and was developed for
use as an adjunctive device for trabeculectomy surgery.
The CM serves as a spacer and a scaffolding to modulate
the fibrotic response as fibroblasts and myofibroblasts
proliferate in response to surgically induced tissue injury.
We hypothesized adjunctive use of the CM at the time of
trabeculectomy would result in similar IOP outcomes but
fewer adverse events compared to MMC.
The success of the use of trabeculectomy with CM
compared to adjunctive therapy with MMC has varied
with respect to the reported outcomes. In a recently
published meta-analysis, the authors found that out-
comes were similar, but pointed out that additional
randomized clinical trials are needed [9]. We report
herein the results of a multicenter randomized clinical
trial designed to compare efficacy and safety of trabecu-
lectomy or combined phacoemulsification and trabecu-
lectomy with MMC versus CM.
Methods
This study was approved by five Institutional Review
Boards with oversight authority of the eight study sites.
The study followed the tenets of the Declaration of
Helsinki, is in compliance with the Health Insurance
Portability and Accountability Act of 1996 and is
registered with ClinicalTrials.gov (NCT01440751). An
independent data safety monitoring committee received
regular reports on surgical outcomes and adverse events
during the course of the study and at its conclusion. The
coordinating center at New York Eye and Ear Infirmary
collected all data regarding the study using a web-based
reporting system.
Inclusion/exclusion criteria
Patients were enrolled at 8 clinical centers, including
private practices and academic medical centers between
February 2012 and December 2012. All clinical investi-
gators were glaucoma subspecialists. Subjects, who were
30 years–of-age or older and in whom trabeculectomy
or combined phacoemulsification and trabeculectomy
had been recommended to manage glaucoma that was
uncontrolled despite medical therapy, were enrolled.
The rationale behind the decision to perform incisional
glaucoma surgery was at the discretion of the individual
surgeons. Patients were eligible if they had primary
open-angle glaucoma, exfoliation glaucoma, pigmentary
glaucoma, corticosteroid-induced glaucoma, or primary
angle-closure glaucoma. Glaucoma was defined as the
presence of optic disc excavation associated with a visual
field defect on standard automated perimetry. Patients
with neovascular glaucoma, glaucoma associated with
uveitis, or glaucoma in aphakic eyes were excluded, as
were those with prior ocular surgery involving a con-
junctival incision. Pseudophakic patients who had under-
gone cataract surgery with a clear corneal incision were
eligible for participation.
All subjects underwent a comprehensive ophthalmo-
logical examination. Baseline IOP was the mean of 2
measurements on 2 separate study visits within 90 days
of surgery. IOP measurements throughout the study
were obtained by an examiner and a separate reader
using a calibrated Goldmann applanation tonometer.
Two measurements were obtained for the study eye and
the mean was used. If the difference between readings
was greater than 2 mmHg, an additional reading was
obtained and the median measurement was used.
Postoperative study visits occurred on postoperative
days 1, 7, 14, 30, and 90 and months 6, 12, 18, and 24.
Automated static perimetry with the Humphrey Visual
Field 24–2 algorithm was performed at baseline, at
months 6, 12, 18, and 24. Stereoscopic optic disc
photographs were obtained at baseline and at months
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12 and 24. Refractions were performed and best spectacle
corrected visual acuity was measured at each study visit.
The randomization process used a sealed envelope
system, the treatment assignment being revealed at the
time of surgery. Subjects were randomized to trabecu-
lectomy with MMC or trabeculectomy with the Ologen
CM. A 1:1 randomization scheme to the two study
arms in blocks of 15, by study site, was used to ensure
that each site had a similar number of subjects assigned
to the each of the two groups.
Surgical procedure
The trabeculectomy was performed according to surgeon
preference. For the MMC group, the concentration of the
drug was 0.4 mg/mL. The duration of application was at
the discretion of the surgeon. Manipulation of scleral flap
sutures with laser suture lysis, removal of releasable
sutures and trans-conjunctival needle revision (TCNR)
were performed at the discretion of the surgeon and
were not counted as complications or as indicators of
surgical failure.
For the CM group, no intraoperative antifibrotic
therapy was utilized. The CM used was the 12-mm
diameter disc with a thickness of 1 mm. The disc was
placed over the scleral flap and under the conjunctiva
prior to closure.
Complete and qualified success criteria
The criteria for the definition of complete success were
IOP >5 and ≤21 mmHg with at least a 20% reduction
below the mean of the two baseline study visit IOPs, and
without subsequent ocular hypotensive medication or
additional glaucoma surgery. Qualified success was
defined by the same criteria but with one or more
ocular hypotensive medications to meet IOP criteria.
Overall success was the combined complete and
qualified success rates. Failure was defined if any of
the IOP criteria for success were unmet on two con-
secutive study visits starting with the six-month visit;
however, the date of failure was defined as the first
study visit when at least one of the criteria was unmet. If
failure based on IOP criteria occurred at the final study
visit (at the 24 month visit or an earlier visit in subjects
for whom additional follow-up is unavailable), failure was
defined to have occurred on that final visit even if failure
criteria were not met on two consecutive visits.
An alternate definition of success with a more stringent
upper limit threshold of ≤17 mmHg (a commonly used
cutpoint in glaucoma clinical trials) was also evaluated.
For both sets of criteria, ≤17 and ≤21 mmHg, qualified
success was defined to have occurred if one or more
ocular hypotensive medications was in use. Beginning
with the six-month visit, as soon as an ocular
hypotensive medication was in use at the time of a
study visit, only qualified success could be achieved,
even if medications were later withdrawn and success
criteria were met.
If additional glaucoma surgery was performed, failure
was defined to have occurred on that date, at any point in
the study, even prior to the six-month visit. Needle revi-
sions were not classified as additional glaucoma surgery.
For each of the four Kaplan-Meier survival curves
generated with the above criteria for success and overall
success, log-rank tests were used to test for statistical
significance between the two groups. As an ancillary
analysis, the same procedures were repeated after
excluding the subjects who underwent combined
phacoemulsification surgery and trabeculectomy. Simi-
larly, the data were also reanalyzed after reclassifying as
successes the subjects who failed by meeting the
numerical definition of hypotony (≤5 mmHg), but in
whom there were no structural (hypotony maculopathy,
optic disc edema, choroidal detachment) or functional
(loss of visual acuity) consequences of the low IOP and
in whom no surgical intervention was utilized to correct
the hypotony.
Ocular hypotensive medical therapy
A washout was not required at the time of enrollment
or for the baseline study visits. Throughout the clinical
trial, the use of ocular hypotensive medications was at
the discretion of the each investigator. The number of
medications in use was determined based on the number
of ocular hypotensive medication classes used. A fixed
combination agent with two classes of medication was
counted as two medications. The mean number of
medications used in each group, at each study visit, was
compared with the Mann–Whitney U test.
Adverse events
Throughout the study, all adverse events were recorded
and submitted to the coordinating center. Hypotony-
related complications were recorded at each study visit.
Hypotony was defined as IOP ≤5 mmHg on two con-
secutive visits occurring at the six month visit or there-
after. Additionally, hypotony was defined to have occurred
if the IOP was ≤5 mmHg at the final visit. A Kaplan-Meier
analysis with a log-rank test for significance was performed
to ascertain differences in the incidence of hypotony
between groups. An alternate statistical analysis was
performed after excluding the cases of hypotony in
which, although the IOP was ≤5 mmHg, there were no
structural or functional consequences of the low IOP as
described above.
Power and sample size calculation
The original power calculation determined that 64
patients per arm were needed to detect a late hypotony
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rate of 24.8% in the MMC group versus 5.0% in the CM
group, with 80% power with a two-tailed test and a Type
I error rate of 5%. Power was maintained at 80% to
detect the observed late hypotony rates of 18.8% in the
MMC group of 48 patients versus 0% in the CM group
of 46 patients (1% rate assumed for power calculation)
with a two-tailed .05 level test.
A non-inferiority power calculation for the hazard
ratio (failure rate in CM vs failure rate in MMC)
indicated that with the study sample size, there was 80%
power to detect a non-inferiority margin up to 1.87 with
a 5% Type I error rate. A proportional hazards analysis
of complete success gives a hazard ratio of 0.65 with an
upper confidence limit of 1.08. This indicates that the
failure rate in the CM group is well below that in the
MMC group with a worst case scenario being only 8%
higher than the MMC group.
Statistical analysis
For continuous measures such as IOP, IOP reduction,
number of medications and visual acuity, group compari-
sons were made at each time point with an independent
sample t-test. Results were verified with the Wilcoxon
rank sum test. Categorical variables were compared
between groups with Fisher’s exact test. Time to success
was summarized with Kaplan-Meier curves and compari-
sons made with the log-rank test. Success rates were
compared between groups adjusting for age, sex and
combined subsequent or prior cataract surgery with Cox
proportional hazards regression. An intent-to-treat
analysis was performed with two exceptions. One patient
in the MMC group did not undergo trabeculectomy, was
withdrawn from the study at the time of surgery and did
not have any follow-up and outcome data. Both eyes of
one patient were randomized; one eye was randomly
selected for statistical analysis. Alpha-level was set at 5%.
Results
One hundred potential eyes of 99 subjects were assessed
for eligibility (Fig. 1). Four declined to participate and a
decision was made to cancel the plan for trabeculectomy
in one subject due to improved IOP. Ninety-five eyes of
94 subjects were randomized. One subject allocated to
the MMC group did not undergo trabeculectomy due to
an intraoperative cataract surgery complication – this
subject was not included in the analysis because no
post-operative data were available. In a protocol viola-
tion, both eyes of one subject were enrolled. Both eyes
were randomized to the CM group. One eye was
randomly selected for analysis. Results are reported for
48 eyes of 48 patients in the MMC group and 45 eyes of
45 patients in the CM group. Demographic and baseline
clinical characteristics were statistically similar between
groups and are summarized in Table 1.
Data regarding cataract surgery are summarized in
Table 2. Despite randomization, 22 subjects in the MMC
group and 11 in the CM group were pseudophakic at
the time of enrollment (p = 0.05). Four subjects in the
Fig. 1 Patient flow chart from enrollment through 24 months. Abbreviations: IOP = Intraocular Pressure; MMC =Mitomycin C; CM= Collagen Matrix
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MMC group and 6 subjects in the CM group underwent
combined cataract surgery, intraocular lens implantation
and trabeculectomy (combined surgery, p = 0.51). Due to
the small number of combined surgery cases, a statistical
analysis of success in that subgroup would not be mean-
ingful and was not performed. During the two-year
follow-up interval, 7 eyes in the MMC group and 6 in the
CM group underwent cataract surgery. The proportions
of eyes in the two groups that underwent cataract surgery
during the follow-up interval, expressed as a proportion of
those at risk (i.e., those that were phakic) were statistically
similar between groups (p = 0.32).
Intraocular pressure, visual acuity and visual field
outcomes
IOP (Fig. 2, Additional file 1: Table S1) and percent
reduction in IOP from baseline (Fig. 3, Additional file 2:
Table S2) as well as mean number of ocular hypotensive
medications (Fig. 4, Additional file 3: Table S3) were
statistically similar for all time points. Visual acuity
(Additional file 4: Table S4), visual field mean deviation,
and rates of visual field change (Additional file 5: Table S5)
were statistically similar between groups at all time points.
Surgical success rates are summarized in Additional
file 6: Table S6. Complete surgical success rates with
cutoff criteria of IOP ≤21 mmHg (Fig. 5) or ≤17 mmHg
(Fig. 6) along with ≥20% reduction below medicated
baseline and IOP >5 mmHg were similar in both groups
(p = 0.112 and 0.16, respectively). After exclusion of 10
subjects who underwent combined phacoemulsification
Table 1 Demographics and baseline characteristics
Mitomycin-C (n = 48) Collagen matrix (n = 45) p-Value (Fisher’s
Exact Test)
Sex N (% Male) 28 (58%) 21 (47%) 0.18
Age (Years) Mean (SD) 71.1 (10.0) 69.4 (10.7) 0.41
Median (IQR) 71.5 (65–79) 71.0 (63–79)
Race European-Derived 38 (79%) 33 (73%) 0.42 (one p-value for
multicategory race)
African-Derived 8 (17%) 9 (20%)
Asian 1 (2%) 2 (4%)
Other 1 (2%) 1 (2%)
Diagnosis N (%) Primary Open Angle Glaucoma 43 38 0.35 (one p-value for
multicategory diagnosis)
Pigmentary Glaucoma 0 3
Primary Angle Closure Glaucoma 3 2
Corticosteroid Induced Glaucoma 1 0
Pseudoexfoliation Glaucoma 1 1
Mixed Mechanism 0 1
Visual Acuity (Log MAR) Mean (SD) 0.18 (0.26) 0.17 (0.23) 0.81
Median (IQR) 0.10 (0–0.21) 0.10 (0–0.30)
Visual Field Mean Deviation Mean (SD) −14.1 (10.7) −12.9 (8.6) 0.55
Median (IQR) −14.4 (−23.3 − −6.4) −14.1 (−19.9 − −5.8)
Baseline IOP (mm Hg) Mean (SD) 20.4 (6.0) 21.2 (6.1) 0.49
Median (IQR) 19.8 (16.0–23.6) 19.0 (17.0–26.0)
Number of Medications Mean (SD) 3.21 (1.13) 3.07 (1.00) 0.53
Median (IQR) 3 (2–4) 3 (2–4) 0.48
SD standard deviation, IQR interquartile range, Log MAR logarithm of the minimum angle of resolution, IOP intraocular pressure
Table 2 Cataract surgery
Mitomycin-





















Rate 31.8% 17.9% 0.32
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and trabeculectomy, there remained no significant dif-
ference in success rates (p = 0.24 and 0.37 for IOP ≤21
and ≤17 mmHg, respectively). There were 3 subjects,
all in the MMC group, in whom the numerical criterion
for hypotony (IOP ≤5 mmHg on two consecutive study
visits) was met, but in whom there were no structural
or functional consequences of hypotony. After redefining
these 3 subjects as surgical successes, there remained no
significant difference between groups (p = 0.23 and 0.31
for IOP ≤21 and ≤17 mmHg, respectively).
The overall success rates (combined complete and
qualified success, with medication) with the same
criteria were significantly better in the CM group for
IOP cutoff ≤21 mmHg (p = 0.007, Fig. 7) and IOP cutoff
≤17 mmHg (p = 0.041, Fig. 8). The difference remained
statistically significant for IOP cutoff ≤ 21 mmHg after
excluding the combined surgery eyes (p = 0.014) but not
for IOP cutoff ≤ 17 (p = 0.087). After redefining the 3 sub-
jects with hypotony based only on numerical criteria as
successful, overall success rate remained significantly
better in the CM group (p = 0.020 and 0.010, respectively,
for IOP cutoff ≤ 21 and ≤ 17 mmHg). After adjusting for
the occurrence of cataract surgery (prior to enrollment,
combined with trabeculectomy or during the course of
the follow-up period), overall success (cutoff ≤21 mmHg)
remained significantly better in the CM group (p = 0.031),
with other success outcomes being non-significant
(complete success with cutoff ≤21 mmHg – p = 0.21, over-
all success with cutoff ≤17 mmHg – p = 0.11, complete
success with cutoff ≤17 mmHg – p = 0.29). At each time
point, numbers at risk in Figs. 5, 6, 7 and 8 may be less
than the number of patients followed to that time point
due to removal from the risk set for success in the
Kaplan-Meier curves.
Adverse events
Early, transient hypotony as well as associated complica-
tions such as hypotony maculopathy and serous choroidal
detachment occurred more frequently in the CM group;
however, the difference was not statistically significant
(Table 3). Hypotony and its sequelae resolved in all of
these subjects prior to the six-month study visit.
Nine subjects in the MMC group and none of the sub-
jects in the CM group met the criteria for persistent hy-
potony as defined in the Adverse Events subsection in
the Methods section above. The risk of persistent hypotony
Fig. 2 Mean intraocular pressure at each study visit in the collagen matrix (CM) and mitomycin-C (MMC) groups (p > 0.05 comparing CM with MMC at
all the time points). The error bars represent standard deviations. Abbreviations: IOP = Intraocular Pressure; MMC =Mitomycin C; CM= Collagen Matrix
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Fig. 4 Mean number of ocular hypotensive medications at the baseline visit prior to surgery and each subsequent study visit in the collagen
matrix (CM) and mitomycin-C (MMC) groups (p < 0.05 by Wilcoxon rank sum test at days 1 and 7).
Fig. 3 Mean percent reduction in intraocular pressure from the mean of the two baseline visits at each subsequent study visit in the collagen matrix
(CM) and mitomycin-C (MMC) groups (p > 0.05 comparing CM with MMC at all the time points). The error bars represent standard deviations
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was significantly higher for the MMC group compared to
the CM group (p = 0.002, Kaplan-Meier analysis, log rank
test, Fig. 9). Six eyes with persistent hypotony had func-
tional damage manifested as a reduction in visual acuity
of at least 2 lines attributable to hypotony. Three eyes
with IOP ≤5 mmHg on two consecutive visits, meet-
ing the study definition for persistent hypotony had
no structural or functional consequences attributable
to hypotony. All 3 subjects were in the MMC group.
When these subjects were re-classified as not meeting
the criteria for persistent hypotony, the risk of per-
sistent hypotony remained significantly higher in the
MMC group (p = 0.022). Similarly, when the subjects
who underwent phacoemulsification combined with trabe-
culectomy were excluded, the difference remained statisti-
cally significant (p = 0.002).
Other adverse events are presented in Table 3. There
were no significant differences in the occurrence of any
other adverse event. Transconjunctival needle revision
(TCNR) was performed only one time in each of 4
subjects in the MMC group (with adjunctive 5-FU in 2
eyes and with MMC in 2 eyes) and 2 subjects in the
CM group (twice in one subject – once without an
antifibrotic agent and once with 5-FU) and once with
MMC in one subject who underwent drainage device
shunt surgery and failed on that basis prior to the
one-year study visit). The need to undergo TCNR did
not constitute an event that was defined as resulting in
surgical failure. Additional glaucoma surgery (drainage
device implantation) was performed in 3 subjects in the
MMC group and 2 in the CM group.
Discussion
Trabeculectomy remains the most commonly performed
incisional glaucoma operation, particularly in eyes for
which a low target IOP is desired. Refinements to the
procedure aimed at improving the success rate and
reducing the incidence of complications would be of
value. This randomized clinical trial demonstrated
two-year outcomes of trabeculectomy or combined
phacoemulsification and trabeculectomy with adjunctive
MMC are similar to those observed with adjunctive use of
CM with respect to Kaplan-Meier complete success rates
and mean IOP; however, there was a significantly lower
incidence of sustained hypotony in the CM group with
both simple numerical criteria or with more stringent
criteria that require structural or functional conse-
quences of the low IOP.
The complete and qualified success rates observed in
the MMC group were similar to those reported in other
randomized clinical trials. For example, the three-year
complete success rate in the Tube Versus Trabeculectomy
(TVT) study, defined as IOP ≤21 mmHg and 20% below
medicated baseline and >5 mmHg without medica-
tions was 40% and an additional 26% were qualified
successes [10]. With the same criteria for success in this
study 38 and 56% of subjects achieved complete success
and an additional 11 and 22% achieved qualified success
Fig. 5 Kaplan-Meier curve demonstrating complete success rates in the collagen matrix (CM) and mitomycin-C (MMC) groups using the intraocular
pressure criteria > 5 mmHg, ≤ 21 mmHg and 20% below the medicated baseline IOP
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in the MMC and CM groups, respectively. Patients in
TVT, however, had undergone previous conjunctival and/
or cataract surgery whereas only eyes without prior con-
junctival surgery were eligible in the present study. An-
other difference between the two studies is the longer
duration of follow-up in the TVT study; however, inspec-
tion of the Kaplan-Meier survival curves included in the
3-year TVT report suggests there was little difference
in success rates between years two and three.
The Collaborative Initial Glaucoma Treatment Study
(CIGTS) was a clinical trial in which eyes without previous
surgery were randomized to initial treatment with medical
therapy or trabeculectomy [11]. The mean baseline IOP
was substantially higher in the surgery arm of CIGTS
than in the present study, 27.4 ± 5.7 mmHg compared
to 20.4 ± 6.0 mmHg in the MMC group and 21.9 ±
7.4 mmHg in the CM group. This is at least in part due to
the fact none of the CIGTS patients were on medical
therapy and all of the patients in the current study
were on at least one medication at baseline. Although
success rates based on IOP criteria were not reported
for CIGTS, the mean IOP in the surgery arm was
14.4 ± 4.3 mmHg at 3 years compared to 11.8 ± 5.2 in
the MMC group and 12.8 ± 3.7 in the CM group at
2 years [11]. Antifibrotic therapy was limited to the
use of intraoperative and/or postoperative 5-fluorouracil,
possibly accounting for the higher mean IOP at 3 years in
CIGTS.
Other investigators have previously compared the results
of trabeculectomy with MMC with trabeculectomy with
the Ologen CM. In one small, randomized clinical trial
with 15 subjects in each group and one-year follow-up
data, the mean IOP was significantly higher and the
success rate lower in the CM group versus MMC
[12]. Those investigators, however, used a disc with a
thickness of 2 mm and diameter of 6 mm compared
to the 1 × 12 mm diameter disc used in this study.
Late hypotony was observed in 7% of subjects in the
CM group and 20% of subjects in the MMC group;
however, no further details were reported. Histopathology
of implants explanted from human eyes with failed trabe-
culectomies in that study disclosed the presence of
fibroblasts, myofibroblasts, and fibronectin within the
implant and enclosure of the implants by a collage-
nous pseudocapsule [12]. An earlier randomized trial
of 10 subjects in each group conducted by the same
group disclosed lower success rates in the CM group
after one-year follow-up; however, they observed more
avascular areas in the blebs in the MMC group [13].
It is possible the thicker, 2 mm CM disc results in
excessive fibrosis over the scleral flap, resulting in
lower success rates.
Fig. 6 Kaplan-Meier curve demonstrating complete success rates in the collagen matrix (CM) and mitomycin-C (MMC) groups using the intraocular
pressure criteria > 5 mmHg, ≤ 17 mmHg with a 20% below the medicated baseline IOP
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Fig. 7 Kaplan-Meier curve demonstrating overall success rates in the collagen matrix (CM) and mitomycin-C (MMC) groups using the intraocular pressure
criteria > 5 mmHg, ≤ 21 mmHg with a 20% below the medicated baseline IOP with or without the use of medication at the time of the study visit
Fig. 8 Kaplan-Meier curve demonstrating overall success rates in the collagen matrix (CM) and mitomycin-C (MMC) groups using the intraocular pressure
criteria > 5 mmHg, ≤ 17 mmHg with a 20% below the medicated baseline IOP with or without the use of medication at the time of the study visit
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A retrospective study with 33 subjects in each group
similarly had worse outcomes in the CM group [14]. In
the same study, anterior segment OCT imaging dis-
closed no difference in bleb morphology between the
two groups at 30 and 60 days; however, at 90 days, bleb
height was lower with CM but there was no difference
in bleb surface area. In a separate publication, the same
investigators reported the Ologen CM implant was visible
in ASOCT images in one third of eyes at 90 days [15].
Conversely, Marey, et al. [16] and Cillino, et al. [17]
reported similar efficacy at 12 and 24 months of follow-
up, respectively, in randomized clinical trials of MMC
versus CM. The 2 mm thick CM disc was used in both
studies. Senthil, et al. [18] also found similar outcomes at
six months in a randomized clinical trial; however, there
was a higher incidence of hyphema in the CM group that
the authors attributed to the use of loose scleral flap
sutures allowing entry of blood from the surgical incisions
into the anterior chamber.
Two meta-analyses of randomized clinical trials com-
paring adjunctive use of MMC versus the Ologen CM
for trabeculectomy have been published. One encom-
passes 224 participants in 6 clinical trials [19] and the
other 227 eyes in 7 clinical trials [9]. Both disclosed no
significant differences in outcomes; however, the authors
of the latter study cautioned that the evidence is limited
and stated additional randomized controlled trials are
needed.
Studies in which MMC soaked Ologen CM implants
were utilized at the time of trabeculectomy demon-
strated no advantage to trabeculectomy with adjunctive
MMC alone [20]. It is likely the utility of the CM device
is dependent to some degree on fibroblast proliferation
into the implant; therefore, the use of MMC in the
sponge may obviate its benefits.
A small retrospective comparative case series of eyes
that underwent trabeculectomy combined with the
ExPress shunt showed that eyes in which the Ologen
CM was used alone had worse IOP outcomes, a higher
reoperation rate, and a higher rate of bleb leaks com-
pared to eyes that underwent trabeculectomy with Ologen
CM with adjunctive 5-FU or eyes that underwent trabecu-
lectomy with MMC alone [21]. The investigators used the
6- × 2-mm CM implant in this study. A larger retrospective
comparative case series of 49 eyes of 37 patients that under-
went trabeculectomy with the ExPress shunt and Ologen
CM had similar outcomes to those observed in 50 eyes of
48 patients which underwent trabeculectomy with the
ExPress shunt with MMC [22].
Techniques with the use of CM during trabeculectomy
have improved as surgeons have developed more
experience with the device and disseminated knowledge
regarding the optimization of its use. Specifically, due
to the pressure of the CM disc on the scleral flap,
scleral flap sutures must be adjusted to have low ten-
sion when the CM device is implanted. When the
scleral flap sutures are tight, egress of aqueous along
the edges of the scleral flap is insufficient, increasing
the risk of failure. Laser suture lysis of scleral flap
sutures is difficult with the CM material in place; there-
fore, releasable sutures may be preferable when using
CM. The thickness of the CM disc may be important.
We believe the thicker, 2-mm thick disc may result in
the formation of excessive fibrotic tissue overlying the
scleral flap and may result in the application of excessive
pressure on the scleral flap resulting in insufficient egress
of aqueous. Additionally, the conjunctival closure may be
under more tension in some eyes when the thicker CM
implant is utilized, possibly increasing the risk of the
development of a wound leak.
We observed a significantly higher incidence of late
hypotony in the MMC group. It is our impression the
conjunctiva is thicker and less avascular in eyes that
underwent trabeculectomy with CM, reducing the risk
of late hypotony. Indeed, the use of Ologen CM
implantation to treat post-trabeculectomy hypotony
has been reported [23]. Paradoxically, frank hypotony
maculopathy occurred as an adverse event in two
cases in the CM group. Both of these were early and
resolved by 14 and 90 days.









Wound Leak (Within 30 Days
of Surgery)
2 3 0.67
Bleb Leak (After 30 Days from
Surgery)
1 0 0.99
Chalazion 1 0 0.99
Corneal Abrasion 0 1 0.48
Corneal Edema 2 1 0.99
Corneal Haze 0 1 0.48
Cystoid Macular Edema 1 0 0.99
Hyphema 1 0 0.99
Hypotony Maculopathya 0 2 0.24
Iritis 0 1 0.48
Macular Scar 0 1 0.48
Choroidal Neovascularization 1 0 0.99
Serous Choroidal Detachmenta 1 1 0.99
Photophobia 1 0 0.99
Ptosis 1 0 0.99




aAll cases of hypotony maculopathy and serous choroidal detachment
occurred prior to the six-month visit
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Limitations of this study include the fact the surgeons,
of necessity, were not masked to treatment assignment.
Subsequent decisions regarding reoperation for glau-
coma and initiation of medical therapy could have been
subject to bias. Very few subjects underwent reoperation
for glaucoma, only 3 in the MMC group and 2 in the
CM group. Although there was no consensus on this
issue in the World Glaucoma Association Guidelines on
Design and Reporting of Glaucoma Surgical Trials [24],
needle revisions were not classified as additional glau-
coma surgery in this study. Very few subjects underwent
needle revision, and there was no significant difference
in the utilization of this procedure between groups.
An additional limitation of this study relates to the fact
subjects were permitted to undergo combined phacoe-
mulsification and trabeculectomy. Although there was
no significant difference in the number of subjects who
underwent combined surgery, there were 4 such subjects
in the MMC group compared to 6 in the CM group.
Additionally, of the 3 patients with angle closure glaucoma
in the MMC group, 2 underwent combined surgery and
trabeculectomy. Of the 2 in CM, 1 underwent combined
surgery and trabeculectomy. The impact of cataract sur-
gery on IOP outcomes could have been larger in these
patients. Due to the small number of subjects who under-
went combined surgery, it is not possible to meaningfully
analyze outcomes in that subgroup. Unlike the impact of
combining phacoemulsification with minimally invasive
glaucoma surgeries, IOP outcomes tend to be worse in
eyes that undergo combined phacoemulsification and
trabeculectomy versus trabeculectomy alone [25]. Since it
is well established, however, that cataract surgery alone
can result in IOP reduction, an ancillary analysis of
success rates was performed after excluding all 10 subjects
who underwent combined surgery as part of a post-hoc
confirmatory analysis. This did not change any of the basic
statistical conclusions with respect to the IOP-lowering
efficacy of the two treatment assignments except for the
overall success rate (success with or without medication)
with an IOP cutoff of ≤ 17 mmHg. That definition of suc-
cess was found to be significantly better in the CM group
for the entire cohort; however, after exclusion of the com-
bined phacoemulsification and trabeculectomy cases, the
p-value for the difference between groups was no longer
statistically significant at p = 0.087. A proportional hazards
model with age, sex, and combined cataract surgery as
covariates showed no statistically significant influence on
the initial results regarding overall success rates for an
IOP cutoff of 21 mmHg within the limit of our sample size
except the difference in overall success rates for an IOP
cutoff of 17 mmHg was no longer significantly different.
Additionally, our sample size calculation was based on
Fig. 9 Kaplan-Meier curve demonstrating hypotony-free rates in the collagen matrix (CM) and mitomycin-C (MMC) groups using the intraocular
pressure criterion≤ 5 mmHg on two consecutive visits, starting at the 6-month visit. If IOP was≤ 5 mmHg at the final study visit, the patient was
classified as having met the definition of hypotony. The risk of hypotony was significantly higher in the MMC group (p = 0.002)
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failure rates due to hypotony. We chose this outcome
because this was a non-inferiority trial with respect to IOP
reduction, as such, we did not anticipate significant
differences in IOP between the two groups. Given the
surgical technique is very similar between the two groups,
aside from modulation of scarring, non-inferiority trials
are often conducted to test whether one treatment arm
offers a better safety profile [26]. Therefore, our results
should not be used to drive conclusions regarding differ-
ences in IOP-lowering efficacy between the two groups.
Future studies with longer follow-up and larger sample
sizes are warranted for that purpose.
Significantly more subjects in the MMC group had
had prior cataract surgery. Although these were per-
formed via clear corneal incisions, using a proportional
hazards model with age, sex, and prior cataract surgery
as covariates we were not able to demonstrate a statisti-
cally significant impact of previous cataract surgery on
the initial results regarding complete and overall success
rates within the limit of our sample size except for over-
all success with an IOP cutoff of 17 mmHg, which
became non-significantly different.
We followed the methodology of the Tube versus
Trabeculectomy Trial with respect to using a numerical
cutoff for hypotony as part of the definition of success
[10]. This is also consistent with the Guidelines on Design
and Reporting of Glaucoma Surgical Trials consensus
document prepared by the World Glaucoma Association
[24]. Three subjects with hypotony as defined by an IOP
≤5 mmHg did not have adverse structural or functional
outcomes as a result. Sustained hypotony, defined as an
IOP ≤5 mmHg on two consecutive visits beginning with
the six-month visit, was a criterion for failure, and the
incidence of hypotony was significantly higher in the
MMC group with either the simple numerical criterion or
a more conservative definition of hypotony that necessi-
tated the presence of hypotony maculopathy, optic disc
edema, choroidal detachment or a reduction in visual
acuity along with an IOP ≤5 mmHg.
Conclusions
In this two-year randomized clinical trial, no measured
difference in complete success rates were observed
between eyes that underwent trabeculectomy with
adjunctive MMC versus implantation of the Ologen CM.
The risk of sustained hypotony was significantly lower in
the CM group. Additional clinical trials with longer
follow up are needed.
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